Gemcitabine Current Events | Page 6

Gemcitabine Current Events, Gemcitabine News Articles.
Sort By: Most Viewed | Most Recent
Page 6 of 6 | 208 Results
Dialing up chemotherapy for pancreatic cancer with ultrasound
Researchers at Haukeland University Hospital in Bergen, Norway have combined a laboratory ultrasound technique called 'sonoporation' with the commercially-available chemotherapy compound Gemcitabine to increase the porosity of pancreatic cells with microbubbles and to help get the drug into cancer cells where it is needed. They report some initial results at this week's ASA's 171st meeting in Salt Lake City. (2016-05-25)

Chemotherapy plus synthetic compound provides potent anti-tumor effect in pancreatic cancers
Human pancreatic cancer cells dramatically regress when treated with chemotherapy in combination with a synthetic compound that mimics the action of a naturally occurring (2010-03-23)

Study supports activity of GEMZAR in the treatment of early-stage breast cancer
GEMZAR (gemcitabine HCl for injection), approved in combination with paclitaxel (Taxol) in the first-line, post-surgical treatment of metastatic breast cancer, was the subject of a study presented today with encouraging results in the pre-surgical treatment of breast cancer. The study was presented at the 43rd Annual Meeting of the American Society of Clinical Oncology. (2007-06-02)

Time-lapse shows how anticancer and antiviral drugs get into cells
Duke scientists have modeled all of the steps by which nucleosides and their analogs are transported into cells by a specific molecule named the concentrative nucleoside transporter or CNT. The finding, published in Nature, provides important structural information that could be used to design smarter, more specific anticancer and antiviral drugs. (2017-04-17)

A drug that inhibits the Notch signalling process is active in a range of advanced cancers
A new anti-cancer drug that inhibits a key cell signalling process involved in many different cancers has shown that it is capable of stopping the progression of cancer and shrinking tumors; importantly, in rare, less well-studied cancers such as adenoid cystic carcinoma. Dr. Christophe Massard told the 28th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics that the drug LY3039478 was successful in inhibiting the Notch signalling pathway in patients with alterations in the Notch protein. (2016-12-01)

Added benefit of eribulin in breast cancer is not proven
Added benefit of eribulin in breast cancer is not proven The currently available evidence provides (2012-08-16)

EGLN inhibitor protects normal tissue and enables RT in mouse model of pancreatic cancer
Administration of the EGLN inhibitor FG-4592 prior to ablative radiotherapy provided protection against fatal gastrointestinal bleeding and improved survival in a mouse model of unresectable pancreatic cancer. (2019-04-30)

Nonhormonal treatment regimens improve survival in patients with metastatic breast cancer
Nonhormonal treatment regimens, including anthracycline-based regimens and taxanes, have improved overall survival in women with advanced (metastatic or recurrent inoperable) breast cancer over the last 35 years, according to a systematic review published Dec. 9 in the Journal of the National Cancer Institute. (2008-12-09)

Page 6 of 6 | 208 Results
   First   Previous   Next      Last is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to